SCHEMBL701168

SCHEMBL701168

O=C1Nc2ccc(Cl)cc2C1=Cc1ccc(-c2cncc(C(=O)O)c2)o1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 9/20 0.59
PIM2 Q9P1W9 8/20 0.59
FLT3 P36888 2/20 0.56
PIM3 Q86V86 1/20 0.55
RPS6KA3 P51812 1/20 0.52
MEN1 O00255 3/20 0.50
KMT2A Q03164 3/20 0.50
POLB P06746 2/20 0.50
MAPT P10636 2/20 0.50
GAA P10253 1/20 0.50
PKM P14618 1/20 0.50
PPARG P37231 1/20 0.50
NCOA2 Q15596 1/20 0.50
NCOA1 Q15788 1/20 0.50
TGM2 P21980 1/20 0.49
TLK2 Q86UE8 1/20 0.48
RET P07949 1/20 0.48
LRRK2 Q5S007 1/20 0.47
KEAP1 Q14145 1/20 0.47
NFE2L2 Q16236 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL701167 1.00 PIM1 (0.59) PIM1PIM2FLT3PIM3RPS6KA3
SCHEMBL10091652 1.00 PIM1 (0.59) PIM1PIM2FLT3PIM3RPS6KA3
SCHEMBL10091744 0.87 PIM1 (0.78) PIM1PIM2FLT3PIM3RPS6KA3
SCHEMBL31434329 0.87 PIM1 (0.78) PIM1PIM2FLT3PIM3RPS6KA3
SCHEMBL10091645 0.86 PIM1 (0.55) PIM1PIM2FLT3PIM3RPS6KA3
SCHEMBL10091665 0.82 PIM1 (0.82) PIM1PIM2FLT3PIM3RPS6KA3
SCHEMBL10091661 0.82 PIM1 (0.62) PIM1PIM2FLT3PIM3RPS6KA3
SCHEMBL700262 0.81 PIM1 (0.68) PIM1PIM2FLT3PIM3RPS6KA3
SCHEMBL700261 0.81 PIM1 (0.68) PIM1PIM2FLT3PIM3RPS6KA3
SCHEMBL705329 0.81 PIM1 (0.82) PIM1PIM2FLT3PIM3TLK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120190669-A1 OXINDOLE COMPOUNDS CYLENE PHARMACEUTICALS, INC. (US) 2012-07-26 US disclosed
US-8124649-B2 Oxindole compounds CYLENE PHARMACEUTICALS, INC. (US) 2012-02-28 US disclosed
EP-2307421-A1 OXINDOLE COMPOUNDS Cylene Pharmaceuticals, Inc. (US) 2011-04-13 EP disclosed
US-20100041635-A1 OXINDOLE COMPOUNDS CYLENE PHARMACEUTICALS, INC. 2010-02-18 US disclosed
WO-2010002933-A1 OXINDOLE COMPOUNDS CYLENE PHARMACEUTICALS, INC. (US) 2010-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100041635-A1 OXINDOLE COMPOUNDS FLT3, PIM1, PIM2 PIM1 2/4885PIM2 3/4885FLT3 1/4885
US-20120190669-A1 OXINDOLE COMPOUNDS FLT3, PIM1, PIM2 PIM1 2/4885PIM2 3/4885FLT3 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.